

# ASX Announcement

## 24 December 2025

### Change of Director's Interest Notice – Ms K Wenn

Cogstate (ASX:CGS) attaches the Change of Director's Interest Notice ("Appendix 3Y") for Ms Kim Wenn.

The Appendix 3Y covers the purchase of a beneficial interest in shares on 15 December 2025 which was advised to the Company on 24 December 2025.

CGS maintains a Continuous Disclosure Policy and Securities Trading Policy and is in regular communication with its directors about providing CGS securities trading information as soon as possible to the Company Secretary. Directors are aware of CGS's obligations under the Listing Rules, including Listing Rule 3.19A, and under the terms of their letter of appointment agree to provide the relevant information to CGS so that it can meet its disclosure obligations under Listing Rule 3.19A.

The Company Secretary prepares the Appendix 3Y, liaises with the relevant director to ensure the information provided is accurate and then lodges the Appendix 3Y on the ASX Market Announcements Platform. These actions must occur within 5 business days of the date of change of the director's interests.

In this instance, some personal circumstances caused this administrative oversight by the director, resulting in late notice to CGS of the change in the director's interests. While CGS's current arrangements to ensure compliance with Listing Rule 3.19B are adequate and are being enforced, CGS has taken further precautions to ensure this omission doesn't occur again. Ms Wenn is aware of these disclosure obligations, and has implemented personal processes to ensure that future compliance is actioned within required timeframes.

This announcement was authorised for release by a sub-committee of the Board of Directors of Cogstate Ltd.

---

#### About Cogstate

Cogstate Ltd (ASX: CGS) is a neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support partners in the delivery of electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics, and scientific consulting. For over 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions, and the clinical care needs of physicians and patients around the world. In the Healthcare market, Cogstate seeks to provide primary care physicians and consumers with brief, accurate and scientifically validated digital measures of cognition, with a focus on easy to use, self-administered tests that inform patients and save physician time. For more information, please visit [www.cogstate.com](http://www.cogstate.com).

#### **For further information contact:**

Brad O'Connor, Chief Executive Officer, [boconnor@cogstate.com](mailto:boconnor@cogstate.com)

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Cogstate Limited</b>
<b>ABN</b>	<b>80 090 975 723</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Kim Wenn
<b>Date of last notice</b>	28 September 2021

#### Part 1 – Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	<ol style="list-style-type: none"><li>1. Indirect</li><li>2. Indirect</li><li>3. Indirect</li></ol>
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<ol style="list-style-type: none"><li>1. Ronald Carl Spencer (Spouse)</li><li>2. Kimron Trust (Discretionary Trust)</li><li>3. Aa a beneficiary of the Kim Maree Wenn - Panorama Super Fund</li></ol>
<b>Date of change</b>	15 December 2025
<b>No. of securities held prior to change</b>	<ol style="list-style-type: none"><li>1. Ordinary Shares: 900</li><li>2. Ordinary Shares: 11,686</li><li>3. Ordinary Shares: 0</li></ol>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Class</b>	<ol style="list-style-type: none"> <li>1. Ordinary Shares</li> <li>2. Ordinary Shares</li> <li>3. Ordinary Shares</li> </ol>
<b>Number acquired</b>	<ol style="list-style-type: none"> <li>1. Nil</li> <li>2. Nil</li> <li>3. 10,183</li> </ol>
<b>Number disposed</b>	<ol style="list-style-type: none"> <li>1. Nil</li> <li>2. Nil</li> <li>3. Nil</li> </ol>
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<ol style="list-style-type: none"> <li>1. N/A</li> <li>2. N/A</li> <li>3. \$22,259.80</li> </ol>
<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1. Ordinary Shares: 900</li> <li>2. Ordinary Shares: 11,686</li> <li>3. Ordinary Shares: 10,183</li> </ol>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<ol style="list-style-type: none"> <li>1. N/A</li> <li>2. N/A</li> <li>3. Acquired on market at \$2.18 per share</li> </ol>

---

+ See chapter 19 for defined terms.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.